Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 23.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,622 shares of the medical research company’s stock after selling 1,137 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Charles River Laboratories International were worth $718,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Boston Trust Walden Corp boosted its position in Charles River Laboratories International by 2.8% during the second quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock worth $41,381,000 after purchasing an additional 5,375 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in Charles River Laboratories International by 5.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 56,840 shares of the medical research company’s stock valued at $15,401,000 after acquiring an additional 2,739 shares during the last quarter. Natixis purchased a new position in Charles River Laboratories International during the 1st quarter valued at about $1,058,000. Tidal Investments LLC raised its position in Charles River Laboratories International by 99.8% during the first quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company’s stock worth $1,435,000 after acquiring an additional 2,646 shares during the last quarter. Finally, Epoch Investment Partners Inc. lifted its holdings in shares of Charles River Laboratories International by 2,733.4% in the first quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock valued at $67,060,000 after purchasing an additional 238,766 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $180.96 on Friday. The business’s fifty day moving average price is $193.72 and its 200 day moving average price is $209.45. Charles River Laboratories International, Inc. has a twelve month low of $166.87 and a twelve month high of $275.00. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $9.34 billion, a P/E ratio of 21.67, a PEG ratio of 6.22 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.41. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.03 billion. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current year.

Charles River Laboratories International declared that its Board of Directors has approved a share buyback plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Barclays cut their price objective on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Evercore ISI lowered Charles River Laboratories International from an “outperform” rating to an “inline” rating and decreased their price objective for the company from $225.00 to $190.00 in a research note on Monday, October 7th. StockNews.com upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Wednesday, October 16th. Baird R W lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. Finally, Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average price target of $209.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).